Akèy › Kansè nan tete › Oklahoma › Oklahoma City
Etid klinik pou Kansè nan tete nan Oklahoma City, OK
17 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote Oklahoma City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Vanguard Study: Testing a New Way to Screen for Cancer
Ap rekriteVolontè an sante akeyi
- University of Oklahoma Health Sciences Center, Oklahoma City
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- University of Oklahoma, Oklahoma City
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Mercy Hospital Oklahoma City, Oklahoma City
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
Ap rekriteFaz 2
- Oklahoma Proton Center, Oklahoma City
Study of AVZO-021 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Avenzo Therapeutics Recruiting Site, Oklahoma City
Biopsy-site-marker in Breast Cancer
Ap rekriteEtid obsèvasyon
- OU Health Stephenson Cancer Center, Oklahoma City
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Ap rekriteFaz 1
- OU Health Stephenson Cancer Center, Oklahoma City
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Ap rekriteFaz 3
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Ap rekriteFaz 3
- University of Oklahoma Health Sciences Center, Oklahoma City
E-Mindfulness Approaches for Living After Breast Cancer
Ap rekriteFaz 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Ap rekriteFaz 1/2
- University of Oklahoma - Health Sciences Center, Oklahoma City
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Ap rekriteFaz 1/2
- Stephenson Cancer Center Oklahoma University Health, Oklahoma City
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Ap rekriteFaz 3
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- Mercy Hospital Oklahoma City, Oklahoma City
Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy
Ap rekriteFaz 1 bonè
- Stephenson Cancer Center, Oklahoma City
Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer
Ap rekriteEtid obsèvasyon
- OU Health Stephenson Cancer Center, Oklahoma City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #13, Oklahoma City
Etid Kansè nan tete nan lòt vil
- New York City, NY136 etid
- Houston, TX126 etid
- Boston, MA112 etid
- Nashville, TN81 etid
- Los Angeles, CA73 etid
- Edison, NJ68 etid
- St. Louis, MO64 etid
- Queens, NY64 etid
- Durham, NC64 etid
- Chicago, IL59 etid
- Philadelphia, PA56 etid
- Dallas, TX55 etid
Lòt etid nan Oklahoma City
- Kansè Poumon ki pa ti selil28 etid
- Kansè ovè28 etid
- Kansè Endomèt25 etid
- Kansè kolorektal22 etid
- Kansè pwostat21 etid
- Kansè poumon19 etid
- Kansè Metastatik16 etid
- Kansè (tout kalite)14 etid
- Leksemi mieloïd egi14 etid
- Karsinòm selil skuamèz tèt ak kou13 etid
- Kansè vejik11 etid
- Kansè pankreyas11 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.